Clinical Trials Logo

Polycystic Kidney Diseases clinical trials

View clinical trials related to Polycystic Kidney Diseases.

Filter by:

NCT ID: NCT01670110 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney Disease

Pasireotide LAR in Severe Polycystic Liver Disease

SOM230
Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.

NCT ID: NCT01632605 Completed - ADPKD Clinical Trials

The Vienna RAP Pilot Study

RAP
Start date: November 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety of a daily single oral dose of sirolimus in patients with advanced autosomal dominant polycystic kidney disease.

NCT ID: NCT01559363 Completed - Clinical trials for Polycystic Kidney, Autosomal Dominant

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Start date: October 11, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study Phase 1b was to determine the safety, plasma pharmacokinetics, and maximum tolerated dose (MTD) of tesevatinib when administered to participants with autosomal dominant polycystic kidney disease (ADPKD). The primary objective of this study Phase 2a was to evaluate the annualized change in glomerular filtration rate (GFR) in participants with ADPKD when treated with tesevatinib.

NCT ID: NCT01451827 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney Disease

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NOCTURNE
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the short-term effects of two tolvaptan formulations in patients with ADPKD.

NCT ID: NCT01430494 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

OVERTURE
Start date: June 2011
Phase: N/A
Study type: Observational

To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.

NCT ID: NCT01377246 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney Disease

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

ALADIN2
Start date: May 2011
Phase: Phase 3
Study type: Interventional

The general aim of the trial is to assess the efficacy of one year treatment with long-acting somatostatin analogue (Octreotide LAR) compared with placebo in slowing kidney and liver growth rate in patients with ADPKD and moderate/severe renal insufficiency and to assess whether and to which extent this translates into slower renal function decline over 3-year follow-up.

NCT ID: NCT01354405 Completed - Clinical trials for Polycystic Liver Disease

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

RESOLVE
Start date: May 2011
Phase: N/A
Study type: Observational

The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.

NCT ID: NCT01348035 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney Disease

Efficacy Study of Water Drinking on PKD Progression.

ESWP
Start date: April 2011
Phase: N/A
Study type: Observational

This is a prospective 5-year study to compare the change in total kidney volume (TKV) before and after tolvaptan therapy, as the primary endpoint, in patients with ADPKD.

NCT ID: NCT01336972 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney Disease

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function.

NCT ID: NCT01280721 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Start date: November 2010
Phase: Phase 3
Study type: Interventional

ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).